Taking a closer look at medical cannabis

March 29, 2018

Medical marijuana is making its way to a state near you. While it is still illegal in many states, legalization of marijuana is increasing across the country as scientists work to unlock its secrets. Medical marijuana, or cannabis, seems to have magical powers over the human body, with wide-reaching effects for numerous diseases. In fact, science has postulated that cannabis could be a cure-all, helping with chronic pain, seizures, cancer, arthritis, multiple sclerosis, and more. In some ways, this could become a proven truth when shown how the endocannabinoid system within our bodies can affect every system and body function.

Spotlight

Thomson Reuters Recap

Recap from Thomson Reuters aims to provide analysis and advice for biopharmaceutical business development. Recap clients include biotechnology and pharmaceutical companies, universities, investment banking, and venture fi rms.

Other Infographics
news image

What Paraspeckles Can Teach Us About Basic Cell Biology

Infographic | December 1, 2019

Discovering a new type of subnuclear body taught me how pursuing the unexpected can lead to new insights—in this case, about long noncoding RNAs and liquid-liquid phase separation in cells.

Read More
news image

Next-Gen Genetics: Cancer Therapies Create Investment Prospects

Infographic | August 12, 2022

The field (gene therapy) is not standing still, it’s evolving rapidly. If we have this discussion again in 18 months’ time, I don't know what we’ll be using then.

Read More
news image

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body

Infographic | April 16, 2020

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body. This infographic shows the events that occur following SARS-CoV-2 infection

Read More
news image

Building the European biotech sector with world-class science and innovation

Infographic | August 5, 2021

Europe continues to be a powerhouse of science and innovation. The region maintains a clear lead over China, the United States, and the rest of the world in terms of the quality and quantity of its science. For example, Europe is home to 43 of the global top 100 life-science universities, while the United States has 34. Europe is a powerhouse in scientific publishing as well, with roughly twice the output of the United States and three times that of China.Europe also leads in terms of quality, as measured by the number of citations for its publications. More than 40,000 biotech patents have been granted in Europe since 2015, although the region’s 3 percent CAGR in patent approvals between 2015 and 2019 lagged behind that of the United States (4 percent) and was a fraction of China’s (14 percent).Despite Europe’s strength in science and innovation, translation remains the biggest challenge. Translation of science into companies is stagnant. The distribution of newly funded biotechs remains unchanged across geographies over the last six years, and Europe accounts for only 25 percent of new biotechs. Future success will depend on improving the translation of research into new companies, raising more capital, and building entrepreneurial talent.

Read More
news image

RNA sequencing libraries

Infographic | April 7, 2020

As part of our In Focus on RNA sequencing for cancer research, we put together an infographic to provide top tips on the preparation of RNA sequencing libraries, the best metrics to use when analyzing your libraries and suggestions for efficient and effective kits for the preparation of each library type.

Read More
news image

Merck’s 23 CRISPR Patents Leading the way in genome-editing technology

Infographic | April 7, 2020

CRISPR Integration: CRISPR/Cas9 System for insertion in eukaryotic cells Compositions and use of CRISPR/Cas9 to integrate a new sequence of DNA after cutting genomic DNA. CRISPR-chrom: Improves access to the genome so that CRISPR-driven edits can be done more efficiently.

Read More

Spotlight

Thomson Reuters Recap

Recap from Thomson Reuters aims to provide analysis and advice for biopharmaceutical business development. Recap clients include biotechnology and pharmaceutical companies, universities, investment banking, and venture fi rms.

Events